Cardizem Intravenous and Xenleta
Determining the interaction of Cardizem Intravenous and Xenleta and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 and/or P-gp may significantly increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral ketoconazole, a potent CYP450 3A4/P-gp inhibitor, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 58% and 165%, respectively. Coadministration of intravenous lefamulin with oral ketoconazole increased mean lefamulin Cmax and AUC by 6% and 31%, respectively. Increased exposure to lefamulin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death. MANAGEMENT: Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 and/or P-gp may significantly increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral ketoconazole, a potent CYP450 3A4/P-gp inhibitor, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 58% and 165%, respectively. Coadministration of intravenous lefamulin with oral ketoconazole increased mean lefamulin Cmax and AUC by 6% and 31%, respectively. Increased exposure to lefamulin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.
MANAGEMENT: Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: diltiazem
Brand name: Cardizem, Cartia XT, Dilacor XR, Dilt-CD, Diltia XT, Diltzac, Matzim LA, Taztia XT, Tiazac, Cardizem CD, Dilt-XR, Tiazac, Cardizem LA, Tiazac Extended Release Capsules
Synonyms: Cardizem
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Xenleta (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cardizem Intravenous-Xenleta (Lefamulin Injection)
- Cardizem Intravenous-Xenleta (Lefamulin Tablets)
- Cardizem Intravenous-Xeomin
- Cardizem Intravenous-Xerava
- Cardizem Intravenous-Xerese
- Cardizem Intravenous-Xerese Cream
- Xenleta-Cardizem LA
- Xenleta-Cardura
- Xenleta-Cardura XL
- Xenleta-Care One Acid Reducer Plus Antacid
- Xenleta-Care One Sleep Aid
- Xenleta-Careone Acid Reducer